CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

Study acronym: Dual CARCIK
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options. In particular, this study will assess the safety and feasibility of CARCIK-CD123/33 cells infusion in adults and children with R/R AML, ahead of scheduled alloHCT.
Trial Details
NCT Number NCT07877610
Lead Sponsor Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Conditions
(from sponsor)		 AML (Acute Myeloid Leukemia), BPDCN
Related terms Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov